Spirulina-Based drug shows promise against food poisoning
NCT ID NCT04182490
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new oral treatment called LMN-101, made from spirulina, to see if it can prevent or control Campylobacter infection. Healthy volunteers took LMN-101 or a placebo for two days, then were exposed to the bacteria. The goal was to check safety and how well the treatment works. Results could lead to a new way to manage this common cause of food poisoning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LMN-101 (a protein from spirulina that targets Campylobacter bacteria)
- What this could lead to
- If it works, this could lead to a new way to prevent or treat Campylobacter infections, reducing diarrhea and other symptoms.
- What could go wrong
- This is an early Phase 2 trial with only 42 people, so results may not apply to everyone. The treatment is experimental and may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAMPYLOBACTER INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pharmaron
Baltimore, Maryland, 21201, United States